H.C. Wainwright initiated coverage on Kinnate BioPharma with a new price target
$KNTE
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of Kinnate BioPharma with a rating of Buy and set a new price target of $33.00